Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Notes Payables (2016 - 2018)

Viking Therapeutics' Notes Payables history spans 5 years, with the latest figure at $3.7 million for Q1 2018.

  • For Q1 2018, Notes Payables changed N/A year-over-year to $3.7 million; the TTM value through Mar 2018 reached $3.7 million, changed N/A, while the annual FY2017 figure was $3.5 million, 5.55% up from the prior year.
  • Notes Payables for Q1 2018 was $3.7 million at Viking Therapeutics, up from $3.5 million in the prior quarter.
  • Across five years, Notes Payables topped out at $3.7 million in Q1 2018 and bottomed at $304274.0 in Q4 2014.
  • The 5-year median for Notes Payables is $2.5 million (2015), against an average of $2.4 million.
  • The largest annual shift saw Notes Payables soared 721.63% in 2015 before it rose 5.55% in 2017.
  • A 5-year view of Notes Payables shows it stood at $304274.0 in 2014, then skyrocketed by 721.63% to $2.5 million in 2015, then surged by 30.78% to $3.3 million in 2016, then rose by 5.55% to $3.5 million in 2017, then rose by 7.82% to $3.7 million in 2018.
  • Per Business Quant, the three most recent readings for VKTX's Notes Payables are $3.7 million (Q1 2018), $3.5 million (Q4 2017), and $3.2 million (Q3 2017).